THU0270 The Effect of Hydroxychloroquine to the Lipid Profile of Greek Patients with Sjogren’s Syndrome
| Autor: | Michail P. Migkos, Paraskevi V. Voulgari, Chrisoula Iliou, Alexandros A. Drosos, Theodora E. Markatseli |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Drug
medicine.medical_specialty medicine.diagnostic_test business.industry media_common.quotation_subject Immunology Significant difference Arthritis Hydroxychloroquine Retrospective cohort study medicine.disease Gastroenterology General Biochemistry Genetics and Molecular Biology Endocrinology Rheumatology Internal medicine medicine Immunology and Allergy Sjogren s business Lipid profile Dyslipidemia medicine.drug media_common |
| Zdroj: | Annals of the Rheumatic Diseases. 72:A256.3-A256 |
| ISSN: | 1468-2060 0003-4967 |
| DOI: | 10.1136/annrheumdis-2013-eular.798 |
| Popis: | Objectives Hydroxychloroquine (HCQ) is a widely used medicine in the treatment of autoimmune rheumatic diseases. Many scientific studies have highlighted its hypolipidemic effect. We investigated the effect of HCQ to the lipid profile of patients with Sjogren’s syndrome (SS). Methods The current retrospective observational study included 71 female patients diagnosed with SS based on the American European Consensus Criteria, who were treated with HCQ. This drug was given in SS patients for arthralgias or arthritis, as well as to treat sicca symptoms. The patients were tested for lipid profile, more specific, the levels of total cholesterol (CHOL), high density lipoproteins (HDL), low density lipoproteins (LDL), triglycerides (TGL) and atherogenic index before the beginning of treatment with HCQ and 6 months, 1, 3 and 5 years after the treatment with HCQ. The analysis was made for all patients and individually for those who were getting hypolipidemic treatment (21 patients) or not (50 patients). Results All patients were women with average age 64±11 years and average duration of treatment with HCQ 7.2±3.6 years. For all patients was noted statistically significant decrease of total cholesterol (levels before treatment 217±40 and after 5 years 206±32, p=0.006). A statistically significant difference was observed to the levels of HDL (57±14 vs 67±17, p Conclusions The use of HCQ to this particular group of patients with SS, is related to a statistically significant decrease of total cholesterol, increase of HDL and improvement of atherogenic index. Taking under consideration the high safety profile and the low cost of the drug, HCQ can be used to patients with SS and coexisting dyslipidemia. Disclosure of Interest None Declared |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|